---
figid: PMC3804031__nihms509444f3
figlink: /pmc/articles/PMC3804031/figure/F3/
number: Figure 3
caption: 'While these mutant BRAF inhibitors produce improved overall survival in
  the patients with BRAF mutations compared to standard treatment options, a major
  challenge remains: essentially all patients treated with these drugs relapse due
  to the development of drug resistance, with the median TTP of 7 months for vemurafenib
  and 5 months for dabrafenib (, ). Several models for resistance have been proposed:
  1) reactivation of the MEK/ERK pathway bypassing BRAF (e.g., secondary mutation
  in NRAS, hyperactivation/overexpression of C-Raf, or activation of another MAPKK
  COT); or, 2) adaptive dependency upon alternative pathways (hyperactivation/overexpression
  of RTKs, such as PDGFRβ or IGF1R, or the AKT pathway) () (–).'
pmcid: PMC3804031
papertitle: Targeting the RAS oncogene.
reftext: Asami Takashima, et al. Expert Opin Ther Targets. ;17(5):507-531.
pmc_ranked_result_index: '97694'
pathway_score: 0.9532521
filename: nihms509444f3.jpg
figtitle: Targeting the RAS oncogene.
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3804031__nihms509444f3.html
  '@type': Dataset
  description: 'While these mutant BRAF inhibitors produce improved overall survival
    in the patients with BRAF mutations compared to standard treatment options, a
    major challenge remains: essentially all patients treated with these drugs relapse
    due to the development of drug resistance, with the median TTP of 7 months for
    vemurafenib and 5 months for dabrafenib (, ). Several models for resistance have
    been proposed: 1) reactivation of the MEK/ERK pathway bypassing BRAF (e.g., secondary
    mutation in NRAS, hyperactivation/overexpression of C-Raf, or activation of another
    MAPKK COT); or, 2) adaptive dependency upon alternative pathways (hyperactivation/overexpression
    of RTKs, such as PDGFRβ or IGF1R, or the AKT pathway) () (–).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - NRAS
  - AKT2
  - MAP2K2
  - RAF1
  - MAP2K1
  - PDGFRB
  - MAPK1
  - AKT3
  - PDGFRA
  - IGF1R
  - BRAF
  - MAPK3
  - ARAF
  - EGFR
  - KRAS
  - ERBB2
  - HRAS
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: N-Ras
  symbol: N-ras
  source: hgnc_alias_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Rafs
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PDGFR,
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PDGFR,
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: IGF1R,
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: B-RAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Rafs
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Rafs
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: EGFR,HER2,etc
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: C-RAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: EGFR,HER2,etc
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
